ERBB2 and triple-negative breast carcinoma: HR+/HER2- was the most common (57.6%) subtype among MBC patients, followed by HR+/HER2+ (19.0%) and TNBC (triple negative breast cancer) (13.6%) while HR−/HER2+ was the least common (9.8%) subtype.